Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | SAkura: long-term safety and efficacy of satralizumab for NMOSD

Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, comments on the long-term efficacy and safety of satralizumab for the treatment of AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD). Previously reported results from the Phase III SAkuraSky (NCT02028884) and SAkuraStar (NCT02073279) showed that satralizumab reduced the risk of relapse, compared to placebo. To assess long-term outcomes, over 100 patients from the SAkura studies with long-term follow-up data from open-label extensions were investigated. At 3.7 years, 74% and 73% of treated patients were relapse free in the SAkuraSky and SAkuraStar cohorts, respectively. Additionally, 89% (SAkuraSky) and 86% (SAkuraStar) had no sustained worsening of EDSS. Adverse event rates across the treatment period were comparable to those seen in the blinded study period. Overall, these findings support the use of satralizumab, showing that its efficacy is sustained with no changes to the safety profile. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

Disclosures

Dr Levy reports the following disclosures:
Consulting for UCB, Sanofi, Genentech, Alexion, and Horizon